CRISPR Therapeutics AG, a biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has approved its gene-edited cell therapy, CASGEVY™ (exagamglogene autotemcel [exa-cel]), for the treatment of transfusion-dependent beta thalassemia in patients aged 12 years and older. The approval, dated January 16, 2024, marks a significant milestone for the company, which specializes in CRISPR/Cas9 gene-editing technology. The therapy represents a new option for patients suffering from this genetic blood disorder, which previously required regular blood transfusions. The announcement was made in a Form 8-K filing with the Securities and Exchange Commission by CRISPR Therapeutics AG.

CRISPR Therapeutics AG, a biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has approved its gene-edited cell therapy, CASGEVY™ (exagamglogene autotemcel [exa-cel]), for the treatment of transfusion-dependent beta thalassemia in patients aged 12 years and older. The approval, dated January 16, 2024, marks a significant milestone for the company, which specializes in CRISPR/Cas9 gene-editing technology. The therapy represents a new option for patients suffering from this genetic blood disorder, which previously required regular blood transfusions. The announcement was made in a Form 8-K filing with the Securities and Exchange Commission by CRISPR Therapeutics AG.